Oxicam

Last updated
Piroxicam, the most popular drug of the oxicam class. Piroxicam.svg
Piroxicam, the most popular drug of the oxicam class.

Oxicam is a class of non-steroidal anti-inflammatory drugs (NSAIDs), [2] meaning that they have anti-inflammatory, analgesic, and antipyretic therapeutic effects. Oxicams bind closely to plasma proteins. [1] Most oxicams are unselective inhibitors of the cyclooxygenase (COX) enzymes. The exception is meloxicam with a slight (10:1) preference for COX-2, which, however, is only clinically relevant at low doses. [3]

Contents

The most popular drug of the oxicam class is piroxicam. [1] Other examples include: ampiroxicam, droxicam, pivoxicam, tenoxicam, lornoxicam, [1] and meloxicam.

Isoxicam has been suspended as a result of fatal skin reactions. [1]

Chemistry

The physico-chemical characteristics of these molecules vary greatly depending upon the environment. [4]

In contrast to most other NSAIDs, oxicams are not carboxylic acids. They are tautomeric, and can exist as a number of tautomers (keto-enol tautomerism), here exemplified by piroxicam: [2] Piroxicam tautomers.svg

Side effects

The use of NSAIDs can, rarely, trigger severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). [5] Epidemiologic studies and reviews have reported that, among NSAIDs, the oxicam derivatives (e.g., piroxicam, tenoxicam, meloxicam) are associated with a comparatively higher risk of SJS/TEN, particularly early after starting treatment, although the absolute risk remains low. [6] [7]

Isoxicam was withdrawn/suspended from marketing after reports of fatal skin reactions. [8]

References

  1. 1 2 3 4 5 Olkkola KT, Brunetto AV, Mattila MJ (February 1994). "Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents". Clinical Pharmacokinetics . 26 (2): 107–20. doi:10.2165/00003088-199426020-00004. PMID   8162655. S2CID   13300943.
  2. 1 2 Ivanova D, Deneva V, Nedeltcheva D, Kamounah FS, Gergov G, Hansen PE, Kawauchi S, Antonov L (March 2015). "Tautomeric transformations of piroxicam in solution: a combined experimental and theoretical study". RSC Advances . 5 (40). England, UK: Royal Society of Chemistry: 31852–31860. Bibcode:2015RSCAd...531852I. doi: 10.1039/c5ra03653d .
  3. ↑ Mutschler, Ernst; Gerd Geisslinger; Heyo K. Kroemer; Monika Schäfer-Korting (2001). Mutschler Arzneimittelwirkungen: Lehrbuch der Pharmakologie und Toxikologie; mit einführenden Kapiteln in die Anatomie, Physiologie und Pathophysiologie[Mutster medicine effects: Textbook of pharmacology and toxicology; with introductory chapters in anatomy, physiology and pathophysiology] (in German) (8 ed.). Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft. p. 233. ISBN   3-8047-1763-2. OCLC   48723029. OL   12928661M.
  4. ↑ Banerjee R, Chakraborty H, Sarkar M (April 2003). "Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam". Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 59 (6). Elsevier: 1213–22. Bibcode:2003AcSpA..59.1213B. doi:10.1016/S1386-1425(02)00300-1. PMID   12659890.
  5. ↑ Ward, Kristina E.; Archambault, Raoul; Mersfelder, Tracey L. (2010-02-01). "Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature". American Journal of Health-system Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists. 67 (3): 206–213. doi:10.2146/ajhp080603. ISSN   1535-2900. PMID   20101062.
  6. ↑ Mockenhaupt, Maja; Kelly, Judith Parsells; Kaufman, David; Stern, Robert S.; SCAR Study Group. "The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective". The Journal of Rheumatology. 30 (10): 2234–2240. ISSN   0315-162X. PMID   14528522.
  7. ↑ Harr, T.; French, L. E. (2010). "Toxic epidermal necrolysis and Stevens-Johnson syndrome". Orphanet Journal of Rare Diseases. 5 39. doi: 10.1186/1750-1172-5-39 . PMC   3021447 . PMID   21162721.
  8. ↑ Olkkola, K. T.; Brunetto, A. V.; Mattila, M. J. (1994). "Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents". Clinical Pharmacokinetics. 26 (2): 107–120. doi:10.2165/00003088-199426020-00004. PMID   8162655.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.